We have collected information about Sirna Delivery Problems for you. Follow the links to find out details on Sirna Delivery Problems.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · For transfection, the activity of siRNA does not require interaction with chromosomal DNA, whereas shRNA-expressing pDNA requires suitably designed promoters. For delivery, siRNA acts in the cytosol and does not require transport into the nucleus, whereas shRNA acts in the nucleus.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://www.mdpi.com/journal/pharmaceutics/special_issues/drug_delivery_of_siRNA_therapeutics
A combination of chemotherapeutic drugs and siRNA is emerging as a new modality for cancer therapy. A safe and effective carrier platform is needed for combination drug delivery. Here, a functionalized mixed micelle-based delivery system was developed for targeted co-delivery of methotrexate (MTX) and survivin siRNA.
https://www.sciencedirect.com/science/article/pii/S1818087614000646
As one of the most promising drugs for cancer treatment, siRNA has great advantages, such as excellent safety, high efficacy, unrestricted choice of targets and specificity. To solve the delivery problems of siRNA, many delivery systems have been developed.Author: Cong-fei Xu, Jun Wang
http://altogenlabs.com/rna-interference-rnai-services/in-vivo-sirna-delivery-and-tissue-targeting/
Unfortunately, in vivo RNAi studies present many technical challenges due to siRNA instability, delivery inefficiency, incorrect biodistribution, and the difficulties of targeting specific tissues. These technical challenges mean that performing RNAi experiments in animals …
http://www.eurekaselect.com/144854/article
Conclusion: Delivery of siRNA to the target site is the biggest challenge for its application in the clinic. The findings of this review confirmed by encapsulation siRNA in the nanoparticles can overcome these challenges. The rapid progress in nanotechnology has enabled the development of effective nanoparticles as the carrier for siRNA delivery.Author: Neda Shajari, Behzad Mansoori, Sadaf Davudian, Ali Mohammadi, Behzad Baradaran
https://www.sciencedirect.com/science/article/pii/S0168365914005677
Work on oral RNAi delivery itself is at an early stage with most reports focusing on biodistribution or delivery via the specialized intestinal epithelial M cells of the Peyer's patches which may achieve delivery to a limited subset of phagocytic cells with uncertain clinical relevance .Author: D. Haussecker
Searching for Sirna Delivery Problems?
You can just click the links above. The data is collected for you.
